זבסקה
j-c health care ltd - miglustat - קפסולות - miglustat 100 mg - miglustat - miglustat - zavesca is indicated for the oral treatment of mild to moderate type i gaucher disease. zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.
מיגלוסטאט דיפארמה
mbi pharma ltd., israel - miglustat - קפסולה קשיחה - miglustat 100 mg - miglustat
מיגלוסטט ג'י.אל. 100 מג
a.l. medi-market ltd. - miglustat - קפסולות - miglustat 100 mg - miglustat
קסניקל
tzamal bio-pharma ltd - orlistat - קפסולות - orlistat 120 mg - orlistat - orlistat - xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (bmi) greater or equal to 30 kg/m2, or overweight patients (bmi > 28 kg/m2) with associated risk factors.
סרדלגה
sanofi israel ltd - eliglustat - קפסולה קשיחה - eliglustat 84.4 mg - eliglustat
גאלאפולד 123 מג
truemed ltd, israel - migalastat as hydrochloride - קפסולה קשיחה - migalastat as hydrochloride 123 mg
אליי
glaxo smith kline (israel) ltd - orlistat 60 mg - capsules - orlistat - for weight loss in overweight adults, 18 years and older, when used along with a reduced - calorie and low-fat diet.
אמלה % 5
padagis israel agencies ltd, israel - lidocaine; prilocaine - קרם - lidocaine 2.5 %; prilocaine 2.5 % - prilocaine, combinations - prilocaine, combinations - topical anaesthetic for superficial dermal analgesia in connection with insertion of iv catheters, blood sampling and superficial surgical procedures.
פרילידן
halperin n.h. medic ltd, israel - lidocaine; prilocaine - קרם - prilocaine 25 mg / 1 g; lidocaine 25 mg / 1 g - prilocaine
סנדאימון ניאורל 50 מג כמוסות
novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.